Slide background

Answering The Right Questions.

Designing The Right Molecules.

Medicinal Chemistry

WuXi brings a wealth of experience to each drug discovery project. IDSU leaders have broad therapeutic area expertise covering all major disease areas including oncology, immunology, infectious disease, CNS and metabolic. Over the course of their careers the IDSU leadership has collectively worked on more than 240 drug discovery programs generating 140 preclinical candidates (PCC) with 50 reaching the clinic and five approved for market. These earlier successes have continued at WuXi, where they have guided more than 80 programs generating more than 20 PCCs including a candidate designated by the US FDA  as a breakthrough therapy.